Protocols

That big HKEX biotech boom is starting to look shaky; Alnylam gets a green light in the UK for patisiran

The booming biotech market on the Hong Kong exchange may be over before it ever really got started. With trade war tensions running high, the appetite for risk in China has suddenly evaporated, sending shares of China’s first pre-profit biotech to go public — Ascletis — down by 15%. That has the investment community particularly nervous as investors show signs of pulling way back from their bullish track record. So far there are two biotechs which made the HKEX leap, including BeiGene with its whopping $903 million secondary.

With just days to go ahead of the big PDUFA deadline for patisiran, Alnylam $ALNY says that the UK is green lighting their landmark RNAi therapy for the country’s early-access program. This will open the door to this drug for patients suffering from hATTR amyloidosis.

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->